← Eichor
Study identifier: NCT03463252 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC

Condition: Endometrial Cancer · Atypical Endometrial Hyperplasia  ·  Sponsor: West China Second University Hospital

PhasePhase 2/Phase 3
Planned participants224
Who can joinFemale, N/A to 40 Years
Healthy volunteersNo

About this study

Primary end points: This clinical trial is aimed to analyze the effectiveness of Levonorgestrel-Releasing Intrauterine System (LNG-IUS, Mirena®) in the fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma, including pathology response and pregnancy outcome. Second end points: To analyze the appearances of side-effects.

This description comes directly from the study's public registry record.

Talk to the study team

ZHENG Ying, Professor  ·  +8613018256012  ·  935398163@qq.com

CHEN Si Jing, postgraduate  ·  +86218380361314  ·  Zhy_chd@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

West China Second University HospitalChengdu, Sichuan, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03463252